| Tau-Targeting Alzheimer’s Drug from AC Immune, Roche Fails in Phase 2 | Frank Vinluan | 09/23/20 | Europe |
| FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures | Frank Vinluan | 09/05/20 | Boston |
| Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More | Sarah de Crescenzo | 08/21/20 | National |
| Genentech Gets FDA OK for Injectable Rare Neuroimmune Disease Drug | Sarah de Crescenzo | 08/18/20 | San Francisco |
| FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy | Sarah de Crescenzo | 08/07/20 | National |
| Biogen to Pay Denali $1B to Partner on Parkinson’s Drug & Other Neuro Meds | Frank Vinluan | 08/06/20 | San Francisco |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug | Frank Vinluan | 07/29/20 | Europe |
| Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact | Frank Vinluan | 07/14/20 | Boston |
| On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO | Sarah de Crescenzo | 07/06/20 | San Francisco |
| Roche Gets FDA OK for Injectable Version of Breast Cancer Drug | Sarah de Crescenzo | 06/29/20 | San Diego |
| FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products | Joanne S. Eglovitch | 06/25/20 | National |
| AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal | Sarah de Crescenzo | 06/10/20 | National |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs | Sarah de Crescenzo | 05/29/20 | Boston |
| Pliant Pushes Forward With IPO Plans to Back Fibrosis Drug Studies | Frank Vinluan | 05/12/20 | San Francisco |
| Ventus Launches With $60M to Shine Light on Innate Immune System Drugs | Frank Vinluan | 05/06/20 | Boston |
| Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) | Frank Vinluan | 04/22/20 | National |
| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics | Frank Vinluan | 04/08/20 | Boston |
| Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic | Frank Vinluan | 03/12/20 | Boston |
| Amunix Raises $73M to Bring Safer T Cell Engagers to Solid Tumors | Sarah de Crescenzo | 03/04/20 | San Francisco |
| ORIC Pharma Plans IPO to Test Therapies for Drug-Resistant Cancers | Sarah de Crescenzo | 03/02/20 | San Francisco |
| Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More | Frank Vinluan | 02/28/20 | National |
| Bicycle Therapeutics Lands $30M From Genentech in New Cancer R&D Pact | Frank Vinluan | 02/25/20 | Boston |
| Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck | Frank Vinluan | 12/04/19 | San Francisco |
| Led by Gilead Veteran Riva, Glenmark’s Ichnos Steps Out on Its Own | Sarah de Crescenzo | 10/15/19 | New York |
| Herceptin Inventors, Immunology Pioneers Take Home 2019 Lasker Awards | Ben Fidler | 09/10/19 | National |
| San Diego Life Sciences Roundup: SGI-DNA, ZeaKal, DelMar Pharma & More | Sarah de Crescenzo | 09/10/19 | San Diego |
| Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More | Frank Vinluan | 08/23/19 | National |
